19
Participants
Start Date
October 8, 2020
Primary Completion Date
July 31, 2027
Study Completion Date
July 31, 2027
Avelumab
All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
External Beam Radiation Therapy (EBRT)
Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
Lutetium-177 (177Lu)-DOTATATE
"Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart.~This treatment arm is now closed to recruitment."
RECRUITING
Royal North Shore Hospital, Sydney
RECRUITING
Gosford Hospital, Gosford
RECRUITING
Wyong Hospital, Hamlyn Terrace
RECRUITING
Lake Macquarie Private Hospital, Gateshead
RECRUITING
Mid North Coast Cancer Institute - Coffs Harbour Health Campus, Coffs Harbour
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Royal Brisbane and Women's Hospital, Brisbane
RECRUITING
Princess Alexandra Hospital, Brisbane
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Sir Charles Gaidner Hospital, Perth
Melanoma and Skin Cancer Trials Limited
OTHER